NCT06846866View on ClinicalTrials.gov

A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 27, 2025

Primary Completion Date

October 22, 2025

Study Completion Date

October 22, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

BMS-986419

Specified dose on specified days

DRUG

BMS-986419 Matching Placebo

Specified dose on specified days

DRUG

Moxifloxacin

Specified dose on specified days

DRUG

Moxifloxacin Matching Placebo

Specified dose on specified days

Trial Locations (1)

85283

RECRUITING

Celerion, Tempe

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06846866 - A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants | Biotech Hunter | Biotech Hunter